Replies to post #9043 on Ariad Pharmaceuticals Inc fka ARIA

[JJM760]

The Pfe machine is going to get a monster head start with Crizotinib. At this pace, 113 is going to have to 10x better (as the Harv has claimed) to catch up. If they could get the friggin trial started already, this company will be in everyone's cross hairs.

[biomaven0]

We identified a secondary mutation in ALK, F1174L...

These cells contained a novel L1152R ALK secondary mutation. Ba/F3 cells with EML4-ALK L1152R were also resistant to crizotinib

'113 at fairly low concentrations is active against both these mutations, which have both been previously identified by Ariad.

Peter